{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:03:42Z","timestamp":1784592222372,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"DOI":"10.1186\/s12969-026-01221-8","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T15:34:59Z","timestamp":1779723299000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early intensification versus step-up biologic strategies in systemic juvenile idiopathic arthritis: a Bayesian network meta-analysis of remission and safety outcomes"],"prefix":"10.1186","volume":"24","author":[{"given":"Xunwei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"issue":"2","key":"1221_CR1","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132.","journal-title":"J Rheumatol"},{"issue":"9563","key":"1221_CR2","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","volume":"369","author":"A Ravelli","year":"2007","unstructured":"Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767\u201378. https:\/\/doi.org\/10.1016\/S0140-6736(07)60363-8.","journal-title":"Lancet"},{"issue":"4","key":"1221_CR3","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1093\/rheumatology\/keab619","volume":"61","author":"A De Matteis","year":"2022","unstructured":"De Matteis A, Bracaglia C, Pires Marafon D, Piscitelli AL, Alessio M, Naddei R, et al. Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort. Rheumatology (Oxford). 2022;61(4):1621\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/keab619.","journal-title":"Rheumatology (Oxford)"},{"key":"1221_CR4","doi-asserted-by":"publisher","first-page":"1134321","DOI":"10.3389\/fped.2023.1134321","volume":"11","author":"CM Foley","year":"2023","unstructured":"Foley CM, Ferguson PJ. Update on the pathogenesis and management of systemic juvenile idiopathic arthritis. Front Pediatr. 2023;11:1134321. https:\/\/doi.org\/10.3389\/fped.2023.1134321.","journal-title":"Front Pediatr"},{"key":"1221_CR5","doi-asserted-by":"publisher","unstructured":"Granel J, Ravalet A, Daghistani A, Clet J, Richer O, Bailhache M, et al. Anakinra as a first-line therapy for systemic juvenile idiopathic arthritis when nonsteroidal anti-inflammatory drug treatment fails: A single-center French retrospective study. ARP Rheumatol 2024 Oct-Dec;3(4):288\u201394. English. https:\/\/doi.org\/10.63032\/TEVI1838","DOI":"10.63032\/TEVI1838"},{"issue":"4","key":"1221_CR6","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/acr.24853","volume":"74","author":"KB Onel","year":"2022","unstructured":"Onel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles-Han ST, et al. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2022;74(4):521\u201337. https:\/\/doi.org\/10.1002\/acr.24853.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"1221_CR7","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1136\/ard-2024-225851","volume":"83","author":"B Fautrel","year":"2024","unstructured":"Fautrel B, Mitrovic S, De Matteis A, Bindoli S, Ant\u00f3n J, Belot A, et al. EULAR\/PReS recommendations for the diagnosis and management of Still\u2019s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still\u2019s disease. Ann Rheum Dis. 2024;83(12):1614\u201327. https:\/\/doi.org\/10.1136\/ard-2024-225851.","journal-title":"Ann Rheum Dis"},{"issue":"25","key":"1221_CR8","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385\u201395. https:\/\/doi.org\/10.1056\/NEJMoa1112802.","journal-title":"N Engl J Med"},{"issue":"25","key":"1221_CR9","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396\u2013406. https:\/\/doi.org\/10.1056\/NEJMoa1205099.","journal-title":"N Engl J Med"},{"issue":"4","key":"1221_CR10","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1136\/annrheumdis-2018-214104","volume":"78","author":"NM ter Haar","year":"2019","unstructured":"ter Haar NM, van Dijkhuizen EHP, Swart JF, van Royen-Kerkhof A, El Idrissi A, Leek AP, et al. Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study. Ann Rheum Dis. 2019;78(4):484\u201390. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214104.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1221_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/rheumatology\/key262","volume":"58","author":"L Kearsley-Fleet","year":"2019","unstructured":"Kearsley-Fleet L, Beresford MW, Davies R, De Cock D, Baildam E, Foster HE, et al. Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra. Rheumatology (Oxford). 2019;58(1):94\u2013102. https:\/\/doi.org\/10.1093\/rheumatology\/key262 . PMID: 30137641; PMCID: PMC6293481.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1221_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12969-022-00768-6","volume":"20","author":"T Beukelman","year":"2022","unstructured":"Beukelman T, Tomlinson G, Nigrovic PA, Dennos A, Del Gaizo V, Jelinek M, et al. First-line options for systemic juvenile idiopathic arthritis treatment: an observational study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. Pediatr Rheumatol Online J. 2022;20(1):113. https:\/\/doi.org\/10.1186\/s12969-022-00768-6 . PMID: 36482434; PMCID: PMC9730566.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"5","key":"1221_CR13","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1007\/s10067-025-07420-0","volume":"44","author":"J Rogowska","year":"2025","unstructured":"Rogowska J, Kubicka J, Grabowska M, Mirocha G, Roszkiewicz J, Smolewska E. Characterization of Patients with Macrophage Activation Syndrome Secondary to Systemic Juvenile Idiopathic Arthritis. Clin Rheumatol. 2025;44(5):2023\u20139. https:\/\/doi.org\/10.1007\/s10067-025-07420-0 . Epub 2025 Mar 27. PMID: 40146446.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"1221_CR14","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/1756-185X.14681","volume":"26","author":"M Shimizu","year":"2023","unstructured":"Shimizu M, Nishimura K, Iwata N, Yasumi T, Umebayashi H, Nakagishi Y, et al. Treatment for macrophage activation syndrome associated with systemic juvenile idiopathic arthritis in Japan. Int J Rheum Dis. 2023;26(5):938\u201345. https:\/\/doi.org\/10.1111\/1756-185X.14681 . Epub 2023 Mar 27. PMID: 36973039.","journal-title":"Int J Rheum Dis"},{"key":"1221_CR15","doi-asserted-by":"publisher","unstructured":"Parums DV. Editorial: Review articles, systematic reviews, meta-analysis, and the updated Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. Med Sci Monit. 2021 Aug 23;27:e934475. https:\/\/doi.org\/10.12659\/MSM.934475. PMID: 34421116; PMCID: PMC8394590.","DOI":"10.12659\/MSM.934475"},{"issue":"6","key":"1221_CR16","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.medcli.2016.02.025","volume":"147","author":"B Hutton","year":"2016","unstructured":"Hutton B, Catal\u00e1-L\u00f3pez F, Moher D. La extensi\u00f3n de la declaraci\u00f3n PRISMA para revisiones sistem\u00e1ticas que incorporan metaan\u00e1lisis en red: PRISMA-NMA [The PRISMA statement extension for systematic reviews incorporating network meta-analysis: PRISMA-NMA]. Med Clin (Barc). 2016;147(6):262\u20136. https:\/\/doi.org\/10.1016\/j.medcli.2016.02.025. Spanish.","journal-title":"Med Clin (Barc)"},{"issue":"5","key":"1221_CR17","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1093\/aje\/kwx344","volume":"187","author":"J Savovic","year":"2018","unstructured":"Savovic J, Turner RM, Mawdsley D, Jones HE, Beynon R, Higgins JPT, et al. Association Between Risk-of-Bias Assessments and Results of Randomized Trials in Cochrane Reviews: The ROBES Meta-Epidemiologic Study. Am J Epidemiol. 2018;187(5):1113\u201322. https:\/\/doi.org\/10.1093\/aje\/kwx344 . PMID: 29126260; PMCID: PMC5928453.","journal-title":"Am J Epidemiol"},{"key":"1221_CR18","doi-asserted-by":"publisher","first-page":"e074495","DOI":"10.1136\/bmj-2022-074495","volume":"381","author":"MA Puhan","year":"2023","unstructured":"Puhan MA, Sch\u00fcnemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, et al. A guide and pragmatic considerations for applying GRADE to network meta-analysis. BMJ. 2023;381:e074495. https:\/\/doi.org\/10.1136\/bmj-2022-074495.","journal-title":"BMJ"},{"issue":"2","key":"1221_CR19","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/art.41488","volume":"73","author":"P Quartier","year":"2021","unstructured":"Quartier P, Alexeeva E, Constantin T, Chasnyk V, Wulffraat N, Palmblad K, et al. Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb\/IV Open-Label, Randomized Study. Arthritis Rheumatol. 2021;73(2):336\u201346. Epub 2020 Dec 11. PMID: 32783351; PMCID: PMC7898684.","journal-title":"Arthritis Rheumatol"},{"key":"1221_CR20","unstructured":"Kostik MM, Isupova EA, Chikova IA, Dubko MF, Masalova VV, Snegireva LS, et al. Reasons for inactive disease and flare in systemic onset juvenile idiopathic arthritis patients during tocilizumab treatment. Clin Exp Rheumatol 2018 Mar-Apr;36(2):335\u201341. Epub 2017 Dec 15. PMID: 29303703."},{"issue":"1","key":"1221_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12969-018-0236-y","volume":"16","author":"M Bielak","year":"2018","unstructured":"Bielak M, Husmann E, Weyandt N, Haas JP, H\u00fcgle B, Horneff G, et al. IL-6 blockade in systemic juvenile idiopathic arthritis - achievement of inactive disease and remission (data from the German AID-registry). Pediatr Rheumatol Online J. 2018;16(1):22. https:\/\/doi.org\/10.1186\/s12969-018-0236-y . PMID: 29622022; PMCID: PMC5887199.","journal-title":"Pediatr Rheumatol Online J"},{"key":"1221_CR22","doi-asserted-by":"publisher","first-page":"1218312","DOI":"10.3389\/fped.2023.1218312","volume":"11","author":"CM Foley","year":"2023","unstructured":"Foley CM, McKenna D, Gallagher K, McLellan K, Alkhdher H, Lacassagne S, et al. Systemic juvenile idiopathic arthritis: The Great Ormond Street Hospital experience (2005\u20132021). Front Pediatr. 2023;11:1218312. https:\/\/doi.org\/10.3389\/fped.2023.1218312 . PMID: 37780048; PMCID: PMC10536248.","journal-title":"Front Pediatr"},{"key":"1221_CR23","doi-asserted-by":"publisher","first-page":"1535223","DOI":"10.3389\/fped.2025.1535223","volume":"13","author":"X Luo","year":"2025","unstructured":"Luo X, Luo X, Luo Q, Tang X. Disease activity and treatment in patients with juvenile idiopathic arthritis before transfer to adult care: the first survey in China. Front Pediatr. 2025;13:1535223. https:\/\/doi.org\/10.3389\/fped.2025.1535223 . PMID: 40248020; PMCID: PMC12004128.","journal-title":"Front Pediatr"},{"key":"1221_CR24","first-page":"14132","volume":"9","author":"H Xiao","year":"2016","unstructured":"Xiao H, Ma M, Song H, Li J, Tang X, Wang C, et al. Clinically inactive disease status with tocilizumab every 4 weeks in refractory systemic-onset juvenile idiopathic arthritis. Int J Clin Exp Med. 2016;9:14132\u201340.","journal-title":"Int J Clin Exp Med"},{"key":"1221_CR25","doi-asserted-by":"publisher","unstructured":"Gillard L, Pouchot J, Cohen-Aubart F, Kon\u00e9-Paut I, Mouterde G, Michaud M, et al. JAK inhibitors in difficult-to-treat adult-onset Still\u2019s disease and systemic-onset juvenile idiopathic arthritis. Rheumatology (Oxford). 2023;62(4):1594\u20131604. https:\/\/doi.org\/10.1093\/rheumatology\/keac440. PMID: 35920788.","DOI":"10.1093\/rheumatology\/keac440"},{"issue":"1","key":"1221_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12969-025-01057-8","volume":"23","author":"AI Rebollo-Gim\u00e9nez","year":"2025","unstructured":"Rebollo-Gim\u00e9nez AI, Pistorio A, Orsi SM, Ridella F, Aldera E, Carlini L, et al. Frequency of remission achievement in the pre-treat-to-target decade in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2025;23(1):8. https:\/\/doi.org\/10.1186\/s12969-025-01057-8 . PMID: 39849509; PMCID: PMC11755886.","journal-title":"Pediatr Rheumatol Online J"},{"key":"1221_CR27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1546-0096-13-4","volume":"13","author":"MM Kostik","year":"2015","unstructured":"Kostik MM, Dubko MF, Masalova VV, Snegireva LS, Kornishina TL, Chikova IA, et al. Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2015;13:4. https:\/\/doi.org\/10.1186\/1546-0096-13-4 . PMID: 25685108; PMCID: PMC4328569.","journal-title":"Pediatr Rheumatol Online J"},{"key":"1221_CR28","doi-asserted-by":"publisher","unstructured":"Sa\u011f E, Uzuno\u011flu B, Bal F, S\u00f6nmez HE, Demir S, Bilginer Y, et al. Systemic onset juvenile idiopathic arthritis: a single center experience. Turk J Pediatr. 2019;61(6):852\u2013858. https:\/\/doi.org\/10.24953\/turkjped.2019.06.005. PMID: 32134578.","DOI":"10.24953\/turkjped.2019.06.005"},{"key":"1221_CR29","doi-asserted-by":"publisher","unstructured":"Barut K, Adrovic A, Sahin S, Tarcin G, Tahaoglu G, Koker O, et al. Prognosis, complications and treatment response in systemic juvenile idiopathic arthritis patients: a single-center experience. Int J Rheum Dis. 2019;22(9):1661\u20131669. https:\/\/doi.org\/10.1111\/1756-185X.13649 Epub 2019 Jul 4. PMID: 31273940.","DOI":"10.1111\/1756-185X.13649"},{"issue":"7","key":"1221_CR30","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.ard.2025.04.024","volume":"84","author":"A Ravelli","year":"2025","unstructured":"Ravelli A, Rosina S, MacMahon JM, Baird T, Rebollo-Gim\u00e9nez AI, Hinze C, et al. Treating juvenile dermatomyositis to target: Paediatric Rheumatology European Society\/Childhood Arthritis and Rheumatology Research Alliance-endorsed recommendations from an international task force. Ann Rheum Dis. 2025;84(7):1055\u201367. Epub 2025 May 22. PMID: 40410052; PMCID: PMC12229752.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1221_CR31","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1136\/ard-2023-224123","volume":"82","author":"B Shakoory","year":"2023","unstructured":"Shakoory B, Geerlinks A, Wilejto M, Kernan K, Hines M, Romano M, et al. The 2022 EULAR\/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS). Ann Rheum Dis. 2023;82(10):1271\u201385. https:\/\/doi.org\/10.1136\/ard-2023-224123 . Epub 2023 Jul 24. PMID: 37487610; PMCID: PMC11017727.","journal-title":"Ann Rheum Dis"},{"key":"1221_CR32","doi-asserted-by":"publisher","unstructured":"Tarp S, Amarilyo G, Foeldvari I, Christensen R. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomised trials. Ann Rheum Dis. 2015;74(Suppl 2):391\u2013392.https:\/\/doi.org\/10.1136\/annrheumdis-2015-eular.1672","DOI":"10.1136\/annrheumdis-2015-eular.1672"},{"issue":"5","key":"1221_CR33","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.semarthrit.2016.10.008","volume":"46","author":"R Davies","year":"2017","unstructured":"Davies R, Gaynor D, Hyrich KL, Pain CE. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review. Semin Arthritis Rheum. 2017;46(5):584\u201393. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.10.008 . Epub 2016 Nov 1. PMID: 27914689.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"1221_CR34","doi-asserted-by":"publisher","first-page":"e30457","DOI":"10.2196\/30457","volume":"24","author":"S Butler","year":"2022","unstructured":"Butler S, Sculley D, Santos D, Fellas A, Giron\u00e8s X, Singh-Grewal D, et al. Effectiveness of eHealth and mHealth Interventions Supporting Children and Young People Living With Juvenile Idiopathic Arthritis: Systematic Review and Meta-analysis. J Med Internet Res. 2022;24(2):e30457. https:\/\/doi.org\/10.2196\/30457 . PMID: 35107431; PMCID: PMC8851322.","journal-title":"J Med Internet Res"},{"issue":"2","key":"1221_CR35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s13312-021-2155-0","volume":"58","author":"CL Shi","year":"2021","unstructured":"Shi CL, Zhang Y, Zhang ZY, Zhou J, Tang XM. Comparative Efficacy and Safety of Non-Steroidal Anti-Inflammatory Drugs in Patients With Juvenile Idiopathic Arthritis: A Systematic Review and Network Meta-analysis. Indian Pediatr. 2021;58(2):162\u20138. PMID: 33632948.","journal-title":"Indian Pediatr"},{"issue":"1","key":"1221_CR36","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13075-021-02507-w","volume":"23","author":"C Seg\u00fa-Verg\u00e9s","year":"2021","unstructured":"Seg\u00fa-Verg\u00e9s C, Coma M, Kessel C, Smeets S, Foell D, Aldea A. Application of systems biology-based in silico tools to optimize treatment strategy identification in Still\u2019s disease. Arthritis Res Ther. 2021;23(1):126. https:\/\/doi.org\/10.1186\/s13075-021-02507-w . PMID: 33892792; PMCID: PMC8063416.","journal-title":"Arthritis Res Ther"},{"key":"1221_CR37","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3389\/fphys.2012.00056","volume":"3","author":"HW Zimmermann","year":"2012","unstructured":"Zimmermann HW, Trautwein C, Tacke F. Functional role of monocytes and macrophages for the inflammatory response in acute liver injury. Front Physiol. 2012;3:56. https:\/\/doi.org\/10.3389\/fphys.2012.00056 . PMID: 23091461; PMCID: PMC3475871.","journal-title":"Front Physiol"},{"key":"1221_CR38","doi-asserted-by":"publisher","unstructured":"Andersson U, Hyperinflammation. On the pathogenesis and treatment of macrophage activation syndrome. Acta Paediatr. 2021;110(10):2717\u20132722. https:\/\/doi.org\/10.1111\/apa.15900. Epub 2021 May 11. PMID: 33934408.","DOI":"10.1111\/apa.15900"},{"issue":"1","key":"1221_CR39","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12969-022-00725-3","volume":"20","author":"T Welzel","year":"2022","unstructured":"Welzel T, Oefelein L, Twilt M, Pfister M, Kuemmerle-Deschner JB, Benseler SM. Tapering of biological treatment in autoinflammatory diseases: a scoping review. Pediatr Rheumatol Online J. 2022;20(1):67. https:\/\/doi.org\/10.1186\/s12969-022-00725-3 . PMID: 35964053; PMCID: PMC9375310.","journal-title":"Pediatr Rheumatol Online J"},{"key":"1221_CR40","first-page":"425","volume":"19","author":"A Civino","year":"2025","unstructured":"Civino A, Diomeda F, Burrone M, Natoli V, Ravelli A. Update on Biologic Therapy in Juvenile Idiopathic Arthritis: A Five-year Narrative Review. Biologics. 2025;19:425\u201341. PMID: 40717835; PMCID: PMC12297008.","journal-title":"Biologics"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-026-01221-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-026-01221-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-026-01221-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:06:44Z","timestamp":1784588804000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12969-026-01221-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1221"],"URL":"https:\/\/doi.org\/10.1186\/s12969-026-01221-8","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An ethics statement is not applicable because this study is based exclusively on published literature.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"48"}}